Jefferies Remains a Buy on Biogen (BIIB)
Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $250.00. The company’s ...
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Cautious Optimism for Biogen: Hold Rating Amidst European Approval Developments
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...
European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...
Seeking Alpha27d
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
Biogen Inc. (NASDAQ:BIIB) the central nervous system disease drug developer based in Cambridge Massachusetts, reported its Q3 earnings yesterday, Wednesday, October 30. First, let's look at some ...
FierceBiotech28d
Biogen buys in to molecular glues with Neomorph deal worth up to $1.45B
Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...
Biogen Inc.: Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
Yahoo Finance29d
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth
Massachusetts-based company said Wednesday in a statement. While that’s a 6% decline from a year earlier, it beat analysts’ estimates. The results could help Biogen start to restore investor ...
The 400-year-old immigration debate
We’ve debated immigration since Native Americans encountered a group of migrants from England who decided to settle in ...
Investing22d
Biogen's SWOT analysis: stock outlook amid pipeline challenges, market shifts
Biogen, headquartered in Cambridge, Massachusetts, has established itself as a key player in the biopharmaceutical industry, focusing on innovative therapies for neurological conditions.